Navigation Links
Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents
Date:9/10/2009

ARDEE, Ireland, Sept. 10 /PRNewswire-FirstCall/ -- Warner Chilcott plc (Nasdaq: WCRX) announced today that one of its subsidiaries has filed two lawsuits against Lupin Limited and its wholly owned subsidiary Lupin Pharmaceuticals, Inc. (collectively "Lupin") in the District Court for the District of Delaware for infringement of Warner Chilcott's U.S. Patent Nos. 5,552,394 (the "'394 Patent") and 6,667,050 (the "'050 Patent"), which cover oral contraceptives LOESTRIN 24 FE and FEMCON FE, respectively.

The lawsuits are in response to the submission of two Abbreviated New Drug Applications ("ANDAs") to the U.S. Food and Drug Administration ("FDA") by Lupin requesting approval to manufacture and sell generic versions of LOESTRIN 24 FE and FEMCON FE prior to the expiration of the '394 Patent in July 2014 and the '050 Patent in April 2019, respectively.

The Company's lawsuits result in a stay of FDA approval of Lupin's ANDAs for 30 months from the date of the Company's receipt of notice with respect to such ANDAs (subject to the prior resolution of the matters before the court). Under current law, the FDA may not approve Lupin's ANDAs until six months following the date on which the "first filer" with respect to each of LOESTRIN 24 FE and FEMCON FE enters the market. Pursuant to the Company's settlement agreement with Watson Pharmaceuticals, Inc. ("Watson"), the "first filer" with respect to LOESTRIN 24 FE, Watson may not enter the market until the earlier of January 22, 2014 or the date on which another generic version of LOESTRIN 24 FE enters the market. Pursuant to the Company's settlement agreement with a current subsidiary of Teva Pharmaceuticals, Inc. ("Teva"), the "first filer" with respect to FEMCON FE, Teva may not enter the market until the earlier of July 1, 2012 or, among othe
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Video: U.S. Department of Health and Human Services Joins Ad Council and Warner Bros. Pictures to Combat Childhood Overweight and Obesity
2. Warner Chilcott Acquires P&Gs Global Pharmaceuticals Business
3. Warner Chilcott Reports Operating Results for the Quarter Ended June 30, 2009 and Updates 2009 Full Year Guidance
4. Warner Chilcott Announces Receipt of Paragraph IV Certification Notices
5. Warner Chilcott Announces Earnings Release Date and Conference Call For Second Quarter 2009 Financial Results
6. Warner Chilcott to Hold 2009 Annual General Meeting of Shareholders and Special Court-Ordered Meeting of Shareholders
7. Warner Chilcott to Present at Wachovias 19th Annual Mid-Year Equity Conference
8. Senators Webb and Warner Vote to Protect Americas Kids From Tobacco
9. Warner Chilcott to Present at the Goldman Sachs 30th Annual Healthcare Conference
10. Warner Chilcott Announces FDA Acceptance of NDA Submission for Low Dose Oral Contraceptive
11. Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... (PRWEB) May 25, 2013 While some ... those who have died serving our Country, many others ... prolonged partying and recklessness. The DUI attorneys at MacGregor ... DUI checklist to help keep this weekend’s party-goers out ... System , there were more than 950 fatal alcohol-related ...
(Date:5/25/2013)... Life science and analytical reagents are those ... create a new substance with the purpose of making ... as biotechnology reagents. Such reagents are significant in the ... market is driven by factors such as expansion in ... growth in research and rapid commercialization of such products. ...
(Date:5/25/2013)... (HealthDay News) -- Many viruses and parasites that affect ... -- a bacteria-borne illness than can result in liver ... parks, according to a veterinarian. These germs ... the air, said Dr. Susan Nelson, a clinical associate ... of these serious diseases can be fatal, even with ...
(Date:5/25/2013)... 2013 Studies from Johns Hopkins University ... excessive weight and their inability to get adequate sleep. ... weight can naturally relieve many symptoms. , Johns ... sleep quality was significantly associated with overall weight loss, ... dated November 6th, 2012, researchers monitored 77 participants ...
(Date:5/25/2013)... Pradaxa lawsuits filed on ... internal bleeding while using the blood thinner continue to mount ... District of Illinois, Bernstein Liebhard LLP reports. According to ... claims had been filed in the litigation as ... reported by the Court on May 15th. ( In Re: ...
Breaking Medicine News(10 mins):Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 2Health News:Criminal Attorneys Provide Memorial Day Weekend DUI Checklist and Safety Information 3Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Hidden Dangers Dog Dog Parks 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3
... better preventive care, , THURSDAY, Nov. 19 (HealthDay News) -- ... lives, but only 25 percent of adults aged 50 to ... a new report shows. , Prepared by the U.S. Centers ... Association, the report also lays out ways to improve the ...
... more likely to have post-operative complications than those of ... fibroids, according to a study at Henry Ford Hospital. ... leaving the uterus intact and preserving the ability for ... patient can present difficulties for the most experienced gynecologic ...
... ... revitalized and interactive website Monday, November 16, 2009. The new site will be able ... initiated to provide users with an enhanced shopping and ordering experience. , ... (PRWEB) November 18, 2009 -- The new website ...
... , MELVILLE, N.Y., Nov. 19 Long Island IVF, a ... help patients achieve successful pregnancies, is now offering a new ... fertility treatment. Through this program and a partnership with In ... the amount of money couples pay for their comprehensive treatment ...
... and iron deficiency in schoolchildren could be reduced in her ... to be published in the International Journal of Food ... not only cheaper and more readily available than beef but ... Home Economics, at the University of Uyo, has looked at ...
... ... that will be marketed and sold through international distribution channels alongside the Company,s ... ... Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy ...
Cached Medicine News:Health News: Too Few Older Adults Get Recommended Screenings 2Health News: Too Few Older Adults Get Recommended Screenings 3Health News:Patient's weight not linked to success of fibroid surgery 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 2Health News:Great Customer Service Just Got Better as Emedco Announces the Launch of their Completely Updated and Enhanced Website 3Health News:Long Island IVF to Offer IVF Financial Share Program, Limiting Costs and Providing Refunds if IVF is Not Successful 2Health News:Let them eat snail 2Health News:Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution 2Health News:Nutra Pharma Introduces Chronic Pain Reliever, Nyloxin OTC, for International Distribution 3
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation ... global medical technology company, today scheduled a conference call ... of fiscal year 2013, ended April 30, 2013. The ... May 30, 2013. The Company will report financial results ... the markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 22, 2011 Regeneron Pharmaceuticals, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has accepted for review ... Injection for Subcutaneous Use for the prevention of gout ... Prescription Drug User Fee Act (PDUFA), the goal for ...
... Endoscopy, Inc.,s (OTCPK: SNDY) is pleased to announce that ... of $73,895.  Solos Endoscopy has consummated agreements which resulted ... Three Months period ending September 30, 2011.  The signed ... reduction of ongoing expenses by approximately $40,000 per quarter. ...
Cached Medicine Technology:Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 2Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 3Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 4Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 5Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 6Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 7Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review 8Solos Endoscopy Finishes the 3rd Quarter With a Net Profit 2
... eliminate false signals and contamination caused ... Promega Barrier Tips offer performance and ... acids (PCR(a)), radioactive isotopes, tissue culture ... specimens. , Promega Barrier Tips are ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
... contamination, which causes false ... Hydrophobic, nonwicking and self-sealing ... pass through these aerosol-resistant ... to tips with absorption ...
... Filters are ideal for PCR ... for any work where aerosol ... designed for pipetting DNA/RNA solutions, ... other. For applications requiring absolute ...
Medicine Products: